Table 1.
Description of the population.
| Patients’ Characteristics | TAE n = 86 |
TACE n = 179 |
Total n = 265 |
p Value (TAE Versus TACE) |
|---|---|---|---|---|
| Center (Grenoble) * | 0 (0%) | 153 (85.5%) | 153 (57.7%) | <0.0001 |
| Gender (Male) * | 76 (88.4%) | 162 (90.5%) | 238 (89.8%) | 0.591 |
| Age (years old) $ | 69 (61–78) | 63 (57–71) | 65 (58–75) | 0.0003 |
| Performance status (0) * | 65 (75.6%) | 146 (81.6%) | 211 (79.6%) | 0.968 |
| Etiologies of chronic liver disease * | n = 84 | n = 168 | n = 252 | |
| High alcohol intake | 26 (31.0%) | 49 (29.2%) | 75 (29.8%) | |
| NASH | 7 (8.3%) | 16 (9.5%) | 23 (9.1%) | |
| Chronic hepatitis C | 20 (23.8%) | 21 (12.5%) | 41 (16.3%) | |
| Chronic hepatitis B | 4 (4.8%) | 13 (7.7%) | 17 (6.7%) | |
| Co-HBV + HCV | 0 (0%) | 4 (2.4%) | 4 (1.6%) | |
| Alcohol + HBV or HCV | 11 (13.1%) | 20 (11.9%) | 31 (12.3%) | |
| Alcohol + metabolic | 16 (19.0%) | 37 (22.0%) | 53 (21%) | |
| Hemochromatosis | 1 (1.2%) | 6 (3.6%) | 7 (2.7%) | |
| Other etiology | 1 (1.2%) | 2 (1.2%) | 3 (1.2%) | |
| Cirrhosis * | 82 (95.4%) | 159 (88.8%) | 241 (90.9%) | 0.083 |
| Child Pugh class | 0.031 | |||
| A | 77 (89.5%) | 145 (81.0%) | 222 (83.8%) | |
| B | 9 (10.8%) | 34 (19.0%) | 43 (16.2%) | |
| Serum AFP $ | 7 (4–16) | 15 (5–71) | 11 (4–48) | 0.0045 |
| Sum of size of the 2 main nodules $ | 62 (42–90) | 54 (36–81) | 55 (37–83) | 0.1131 |
| Number of nodules | <0.0001 | |||
| Unique nodule * | 8 (9.3%) | 55 (30.7%) | 63 (23.8%) | |
| 2–3 lesions * | 17 (19.8%) | 62 (34.6%) | 79 (29.8%) | |
| ≥4 lesions * | 61 (70.9%) | 62 (34.6%) | 123 (46.4%) | |
| BCLC stage | <0.0001 | |||
| A * | 9 (10.5%) | 64 (35.8%) | 73 (27.6%) | |
| B * | 66 (76.7%) | 84 (46.9%) | 150 (56.6%) | |
| C * | 11 (12.8%) | 31 (17.3%) | 42 (15.9%) | |
| Type of treatment at first TAE/TACE | ||||
| Bilobar treatment * | 74 (86.1%) | 130 (72.6%) | 204 (77%) | 0.050 |
| Lobar treatment * | 11 (12.8%) | 43 (24%) | 54 (20.4%) | |
| Segmental treatment * | 1 (1.2%) | 6 (3.4%) | 7 (2.6%) | |
| Number of procedures $ | 2 (1–2) | 2 (1–2) | 2 (1–2) | 0.7562 |
| Liver transplantation * | 7 (8.1%) | 44 (24.6%) | 51 (19.2%) | 0.001 |
| Treatments following TAE/TACE | ||||
| Radiofrequency ablation | 16 (18.6) | 10 (5.6) | 26 (9.8) | |
| Surgical removal | 0 | 1 (0.6) | 1 (0.4) | |
| Systemic therapiesSorafenib | 23 (26.7) 22 (25.6) |
31 (17.3) 18 (10.1) |
44 (16.6) 40 (15.1) |
|
| Clinical trial | 1 (1.2) | 13 (7.3) | 14 (5.3) | |
| Other treatment (SIRT, alcoholization) | 1 (1.2) | 11 (6.1) | 12 (4.5) | |
| No additional treatment | 19 (22.1) | 45 (25.1) | 64 (24.2) |
* Number (percentages), $ Median (interquartile range); AFP: alphafetoprotein, BCLC: Barcelona Clinic Liver Cancer, HBV: hepatitis B virus, HCV: hepatitis C virus, NASH: non-alcoholic steatohepatitis, SIRT: Selective Internal Radiotherapy, TAE: trans-arterial embolization, TACE: trans-arterial chemoembolization.